- Home
- FDMT vs HPF Comparison
FDMT vs HPF Comparison
Compare FDMT & HPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- HPF
- Stock Information
- Founded
- FDMT 2013
- HPF 2002
- Country
- FDMT United States
- HPF United States
- Employees
- FDMT N/A
- HPF N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- HPF Finance Companies
- Sector
- FDMT Health Care
- HPF Finance
- Exchange
- FDMT Nasdaq
- HPF Nasdaq
- Market Cap
- FDMT 391.8M
- HPF 364.2M
- IPO Year
- FDMT 2020
- HPF N/A
- Fundamental
- Price
- FDMT $9.97
- HPF $16.63
- Analyst Decision
- FDMT Strong Buy
- HPF
- Analyst Count
- FDMT 8
- HPF 0
- Target Price
- FDMT $30.63
- HPF N/A
- AVG Volume (30 Days)
- FDMT 771.6K
- HPF 35.3K
- Earning Date
- FDMT 11-12-2025
- HPF 01-01-0001
- Dividend Yield
- FDMT N/A
- HPF 8.96%
- EPS Growth
- FDMT N/A
- HPF N/A
- EPS
- FDMT N/A
- HPF N/A
- Revenue
- FDMT $33,000.00
- HPF N/A
- Revenue This Year
- FDMT $9,656.76
- HPF N/A
- Revenue Next Year
- FDMT N/A
- HPF N/A
- P/E Ratio
- FDMT N/A
- HPF N/A
- Revenue Growth
- FDMT N/A
- HPF N/A
- 52 Week Low
- FDMT $2.24
- HPF $12.99
- 52 Week High
- FDMT $10.03
- HPF $16.80
- Technical
- Relative Strength Index (RSI)
- FDMT 69.13
- HPF 45.24
- Support Level
- FDMT $8.50
- HPF $16.65
- Resistance Level
- FDMT $10.03
- HPF $17.13
- Average True Range (ATR)
- FDMT 0.64
- HPF 0.14
- MACD
- FDMT 0.07
- HPF -0.05
- Stochastic Oscillator
- FDMT 86.96
- HPF 18.97
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About HPF John Hancock Pfd Income Fund II Pfd Income Fund II
John Hancock Preferred Income Fund II is the United States based closed-end, diversified management investment company. Its primary objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. The fund's principal investment strategies include to invests a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, capital preferred securities and short-term investments.